Jatenzo Medicare Advantage Coverage: How to Get Oral TRT Covered in 2026

What Jatenzo Is and Why Medicare Advantage Plans Treat It Differently

Jatenzo is the only FDA-approved oral testosterone replacement therapy for adult males diagnosed with hypogonadism, a condition defined by serum total testosterone levels consistently below 300 ng/dL combined with clinical symptoms [1]. The FDA granted approval in March 2019 based on two registration trials demonstrating that 87% of men achieved eugonadal testosterone levels (between 300 and 1,100 ng/dL) at the 237 mg twice-daily dose [2].

Medicare Advantage plans (Medicare Part C) bundle hospital, medical, and typically Part D prescription drug coverage into a single plan administered by private insurers like UnitedHealthcare, Humana, Aetna, and Cigna. These plans must cover at least the same drugs as Original Medicare Part D, but each plan builds its own formulary with different tier placements and utilization management rules. Because Jatenzo carries a wholesale acquisition cost of roughly $900 per month, plan sponsors almost universally classify it as a non-preferred brand or specialty-tier medication [3]. That tier placement triggers higher cost-sharing for beneficiaries, which is why understanding the specific formulary rules of your plan matters before filling a prescription.

Topical testosterone gels and patches (like AndroGel, Testim, and Androderm) have been available as generics for years, making them far cheaper for insurers. Plans use this cost difference to justify requiring step therapy. The clinical rationale is straightforward: if a $30-per-month generic gel works, a $900-per-month oral capsule is not medically necessary. Your prescriber's job is to demonstrate why, in your specific case, that logic does not hold.

How to Check Whether Your Medicare Advantage Plan Covers Jatenzo

Start with your plan's formulary. Every Medicare Advantage plan with Part D benefits publishes a formulary document, updated quarterly, that lists covered drugs by tier and notes any restrictions. You can find it on your plan's website, on the Medicare Plan Finder at Medicare.gov, or by calling the member services number on your insurance card.

Search for "testosterone undecanoate" or "Jatenzo" in the formulary index. Three pieces of information matter most: the tier number, the quantity limit, and the utilization management codes. A designation of "PA" means prior authorization is required. "ST" means step therapy applies. "QL" indicates a quantity limit, typically 120 capsules per 30 days (matching the twice-daily dosing schedule).

If Jatenzo does not appear on the formulary at all, you are not out of options. Medicare Part D regulations require plans to grant a coverage determination or exception when a prescriber provides clinical justification that a non-formulary drug is medically necessary [4]. The Centers for Medicare & Medicaid Services (CMS) mandates that plans respond to standard exception requests within 72 hours and expedited requests within 24 hours [5]. Your prescriber submits the request. You should not need to file it yourself.

The Prior Authorization Process Step by Step

Prior authorization for Jatenzo under Medicare Advantage follows a predictable pattern. The plan needs documentation that testosterone replacement is medically indicated and that Jatenzo specifically is the appropriate formulation.

Step 1: Confirm the diagnosis. Your prescriber must document hypogonadism with two separate morning serum total testosterone levels below 300 ng/dL, drawn on different days, consistent with the Endocrine Society 2018 Clinical Practice Guideline [6]. A single low reading is not sufficient. The guideline, authored by Bhasin et al. and published in the Journal of Clinical Endocrinology & Metabolism, explicitly recommends "confirmation of the diagnosis by repeating the measurement of morning total testosterone" before initiating therapy.

Step 2: Document step therapy failure or contraindication. Most plans require that you have tried and failed (or have a documented reason to avoid) at least one topical testosterone formulation. Acceptable reasons include: skin reactions to topical formulations, concern about secondary transfer to household contacts (children, pregnant partners), inability to adhere to the drying time and application-site restrictions, or documented subtherapeutic testosterone levels despite compliant topical use. The American Urological Association (AUA) 2018 guideline acknowledges that "patient preference for route of administration and concern for transference risk are valid considerations in formulation selection" [7].

Step 3: Submit the prior authorization form. Your prescriber's office completes the plan's PA form, attaching lab results, chart notes documenting topical failure or contraindication, and a letter of medical necessity. Turnaround is typically 48 to 72 hours for standard requests.

Step 4: If denied, appeal. Medicare Part D appeal rights are strong. A 2023 HHS Office of Inspector General report found that 60% of Part D prior authorization denials that were appealed at the first level (plan redetermination) resulted in a favorable outcome for the beneficiary [8]. If the plan redetermination fails, the next step is an Independent Review Entity (IRE) appeal, which overturns roughly 40% of remaining denials.

What You Will Pay Out of Pocket Under Medicare Advantage

Your actual cost depends on the plan's tier structure, your phase in the Part D benefit cycle, and whether you qualify for the Low-Income Subsidy (LIS, also called Extra Help). The Inflation Reduction Act capped total annual Part D out-of-pocket spending at $2,000 starting in 2025, and that cap remains in effect for 2026 [9].

Here is a realistic cost scenario. If your plan places Jatenzo on Tier 4 (non-preferred brand) with a 40% coinsurance after a $590 deductible, your first month costs roughly $360 in coinsurance after meeting the deductible. Monthly costs continue at that rate until you reach the $2,000 annual out-of-pocket cap, which happens around month five or six. After that, you pay $0 for the remainder of the calendar year.

For beneficiaries who qualify for full LIS benefits (income below 150% of the federal poverty level), copays are capped at $4.50 for generic drugs and $11.20 for brand-name drugs in 2026 [10]. That means Jatenzo could cost as little as $11.20 per month year-round.

The Medicare Prescription Payment Plan, introduced in 2025, lets all Part D enrollees spread their out-of-pocket costs across monthly installments rather than paying large sums at the pharmacy counter [9]. This does not reduce total spending, but it eliminates the cash-flow shock of a $360 bill in January.

The Manufacturer Patient Assistance Program

Tolmar, the manufacturer of Jatenzo, operates a patient assistance program (PAP) for eligible individuals. Medicare beneficiaries may qualify for assistance through Tolmar's program if they meet income thresholds, though federal anti-kickback statute rules prohibit manufacturers from offering traditional copay cards to Medicare patients [11].

What Tolmar can provide to Medicare beneficiaries is direct drug supply at no cost through a PAP for those meeting financial eligibility criteria. These programs are structured as charitable donations of the drug itself, not as insurance copay offsets. Eligibility typically requires household income below 400% of the federal poverty level ($62,400 for a single individual in 2026) and enrollment in a Medicare Part D plan.

To apply, visit the Tolmar website or call the number on the Jatenzo prescribing information. Your prescriber will need to complete a brief enrollment form. Processing takes two to four weeks in most cases.

For commercially insured patients (not on Medicare), Tolmar offers a separate copay assistance card that can reduce out-of-pocket costs to as low as $0 per month [12]. This card explicitly excludes Medicare, Medicaid, TRICARE, and other federal or state healthcare program beneficiaries.

Alternatives If Coverage Is Denied or Unaffordable

If your Medicare Advantage plan denies Jatenzo after appeals, or if cost-sharing remains prohibitive, several clinical alternatives exist.

Generic topical testosterone. Testosterone cypionate intramuscular injections cost $30 to $60 per month at most pharmacies, and generic testosterone gel 1.62% (the generic equivalent of AndroGel) runs approximately $30 to $80 per month [13]. These are covered on Tier 1 or Tier 2 of virtually every Medicare Part D formulary.

Testosterone cypionate injections (subcutaneous or intramuscular). Self-administered injections of testosterone cypionate 200 mg/mL are the lowest-cost TRT option. A 10 mL vial lasts roughly 10 weeks at standard dosing of 100 mg weekly and can be obtained for under $40 with a GoodRx coupon at major chain pharmacies [13].

Compounded oral testosterone. Some compounding pharmacies prepare oral testosterone formulations, but these are not FDA-approved and are not covered by Medicare Part D. The Endocrine Society does not recommend compounded testosterone products when FDA-approved alternatives are available, citing inconsistent potency and lack of regulatory oversight [6].

Switching Medicare Advantage plans. If your current plan's formulary places Jatenzo in an unfavorable tier or refuses coverage entirely, you can switch plans during the Annual Election Period (October 15 through December 7) or the Medicare Advantage Open Enrollment Period (January 1 through March 31). Before switching, use Medicare Plan Finder to compare Jatenzo-specific cost estimates across available plans in your ZIP code.

Clinical Considerations Specific to Jatenzo Under Medicare

Jatenzo carries a unique safety profile compared to other testosterone formulations. The FDA-approved labeling includes a warning about dose-dependent increases in blood pressure [14]. In the registration trials, systolic blood pressure increased by a mean of 3 to 5 mmHg at the 237 mg dose, and roughly 7.5% of participants experienced blood pressure readings above 140/90 mmHg during treatment [2].

For Medicare-age patients (65 and older), this blood pressure signal matters more than it does for younger men. Hypertension prevalence among U.S. adults aged 65 and older exceeds 70%, according to CDC NHANES data [15]. Your prescriber should monitor blood pressure at baseline, at one month, and periodically thereafter. The prescribing information recommends dose reduction (from 237 mg to 198 mg, or from 198 mg to 158 mg) if blood pressure rises above acceptable thresholds.

A secondary consideration is cardiovascular risk. The TRAVERSE trial (N=5,204), published in the New England Journal of Medicine in 2023, demonstrated that testosterone replacement therapy did not increase the incidence of major adverse cardiovascular events compared to placebo in men aged 45 to 80 with hypogonadism and preexisting or high risk of cardiovascular disease [16]. Dr. Shalender Bhasin, the lead investigator, stated that "testosterone replacement therapy in middle-aged and older men with hypogonadism and preexisting or high cardiovascular risk was noninferior to placebo with respect to the incidence of major adverse cardiac events." This trial used transdermal testosterone gel, not oral Jatenzo, but the finding has broadly reassured clinicians about testosterone safety in older populations.

Polycythemia (hematocrit above 54%) occurs in approximately 3.3% of Jatenzo-treated patients [2]. Medicare Advantage plans typically require a complete blood count at baseline, three months, and annually during testosterone therapy. If hematocrit rises above 54%, current guidelines recommend dose reduction or discontinuation until levels normalize [6].

A Practical Timeline for Getting Jatenzo Covered

Getting Jatenzo approved and filled under Medicare Advantage takes four to eight weeks from first appointment to first prescription in hand. Here is a realistic timeline:

Week 1: Prescriber orders two morning testosterone levels drawn on separate days. Labs return within three to five days.

Week 2: If both levels confirm testosterone below 300 ng/dL, prescriber initiates prior authorization. If your plan requires step therapy documentation and you have not previously tried topical testosterone, your prescriber may need to document a clinical contraindication or prescribe a 30-day trial of topical gel first.

Weeks 3 to 4: Plan responds to prior authorization (72-hour standard turnaround). If approved, the prescription is sent to your Part D pharmacy.

Weeks 5 to 6 (if needed): If denied, prescriber files a plan redetermination appeal with additional clinical documentation. Response within 7 calendar days.

Weeks 7 to 8 (if needed): If the plan upholds the denial, you file with the IRE. Response within 7 calendar days for standard appeals.

A 2024 KFF analysis found that the median time from initial prior authorization request to final resolution (including one appeal) for specialty drugs under Medicare Part D was 18 days [17]. Starting the process before your current testosterone supply runs out avoids gaps in therapy.

Jatenzo dosing starts at 237 mg twice daily, taken with food, with serum testosterone levels checked after approximately four to six weeks to confirm the level falls between 300 and 1,100 ng/dL and to reassess blood pressure [14].